

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

SEC 1473 (7-02)

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)	-						
1. Name and Address of Reporting Person [*] Greenberg Eric Howard	2. Date of Event Requiring Statement (Month/Day/Year) 08/15/2022	3. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]					
(Last) (First) (Middle) C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., SUITE 505	06/13/2022	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner Officer (give titleOther (specify			5. If Amendment, Date Original Filed(Month/Day/Year)		
^(Street) SOUTH SAN FRANCISCO, CA 94080		below) below)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I	Table I - Non-Derivative Securities Beneficially Owned					
1. Title of Security 2. Amount (Instr. 4) (Instr. 4) Beneficially (Instr. 4)			3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock	0 <u>(1)</u>	0 (1)					

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond
unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exer	rcisable	3. Tit	le and Amount of	4. Conversion	5. Ownership	6. Nature of Indirect Beneficial
(Instr. 4)	(Month/Day/Year)		1 5 8		or Exercise	Form of	Ownership
					Price of	Derivative	(Instr. 5)
			(Instr. 4)		Derivative	Security: Direct	
	Date	Expiration			Security	(D) or Indirect	
	Exercisable	Date	Title	Amount or Number of Shares		(I)	
Exclusion	Encreisable	Dute		Shares		(Instr. 5)	

Reporting Owners

		Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Greenberg Eric Howard C/O TITAN PHARMACEUTICALS, INC. 400 OYSTER POINT BLVD., SUITE 505 SOUTH SAN FRANCISCO, CA 94080	Х					

Signatures

/s/ Eric Greenberg	08/25/2022	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) No securities are beneficially owned.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.